Autophagy-Lysosomal Dysfunction in Neurodegenerative Diseases

Autophagy-Lysosomal Dysfunction in Neurodegenerative Diseases

Overview

[Autophagy](/entities/autophagy)-lysosomal pathway dysfunction is a central mechanism underlying protein aggregation and neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. The autophagy-lysosomal system (ALS) is responsible for clearing damaged organelles, misfolded proteins, and protein aggregates. When this system fails, toxic protein species accumulate, leading to cellular dysfunction and death. [@menzies2019]

This integration page examines how autophagy and lysosomal function become impaired across neurodegenerative diseases, the consequences of this dysfunction, and therapeutic strategies targeting protein clearance pathways. The understanding of autophagy-lysosomal dysfunction has advanced significantly in recent years, with new therapeutic modalities emerging from basic research to clinical testing. [@auto_lysosome_2024]

The Autophagy-Lysosomal System

Types of Autophagy

The autophagy system encompasses several distinct pathways: [@schondorf2014]

Macroautophagy involves the formation of double-membraned autophagosomes that engulf cytoplasmic contents and fuse with lysosomes. This is the primary pathway for clearing large protein aggregates and damaged organelles. Macroautophagy can be selective (for specific cargo) or non-selective (bulk degradation). Key regulators include the ULK1 complex, Beclin-1, and the ATG5-12/ATG16L1 conjugation system. [@gao2019]

Autophagy-Lysosomal Dysfunction in Neurodegenerative Diseases

Overview

[Autophagy](/entities/autophagy)-lysosomal pathway dysfunction is a central mechanism underlying protein aggregation and neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. The autophagy-lysosomal system (ALS) is responsible for clearing damaged organelles, misfolded proteins, and protein aggregates. When this system fails, toxic protein species accumulate, leading to cellular dysfunction and death. [@menzies2019]

This integration page examines how autophagy and lysosomal function become impaired across neurodegenerative diseases, the consequences of this dysfunction, and therapeutic strategies targeting protein clearance pathways. The understanding of autophagy-lysosomal dysfunction has advanced significantly in recent years, with new therapeutic modalities emerging from basic research to clinical testing. [@auto_lysosome_2024]

The Autophagy-Lysosomal System

Types of Autophagy

The autophagy system encompasses several distinct pathways: [@schondorf2014]

Macroautophagy involves the formation of double-membraned autophagosomes that engulf cytoplasmic contents and fuse with lysosomes. This is the primary pathway for clearing large protein aggregates and damaged organelles. Macroautophagy can be selective (for specific cargo) or non-selective (bulk degradation). Key regulators include the ULK1 complex, Beclin-1, and the ATG5-12/ATG16L1 conjugation system. [@gao2019]

Microautophagy involves direct engulfment of cytoplasm by lysosomal membrane invagination. This process occurs at the lysosomal surface and is mediated by lysosomal membrane proteins. While less characterized than macroautophagy, microautophagy contributes to organelle quality control and may be particularly important for mitochondrial turnover. [@khandelwal2019]

Chaperone-mediated autophagy (CMA) selectively degrades proteins containing a KFERQ motif, mediated by Hsc70 and LAMP-2A. CMA is unique among autophagy pathways as it does not require membrane remodeling. Proteins are directly translocated across the lysosomal membrane via the LAMP-2A receptor. CMA is particularly important for degrading damaged or oxidized proteins and is impaired with aging. [@scrivo2018]

Mitophagy is the selective autophagy of mitochondria, critical for maintaining neuronal health. The PINK1-PARKIN pathway is the best-characterized mitophagy mechanism: upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane, phosphorylates ubiquitin and PARKIN, triggering recruitment of autophagy receptors (p62, OPTN, NDP52) that link mitochondria to the growing autophagosome. [@mitophagy_2024]

Lysosomal Function

Lysosomes contain hydrolytic enzymes that degrade proteins, lipids, nucleic acids, and carbohydrates. Lysosomal function depends on: [@kocaturk2018]

• Acidification: V-ATPase pumps protons into the lysosome (optimal pH 4.5-5.0)
• Enzyme activity: Cathepsins B, D, L are major proteases
• Membrane integrity: Prevents enzyme leakage into cytosol
• Autophagy flux: Complete autophagic degradation
• Calcium storage: Lysosomes are calcium stores that regulate fusion events

Disease-Specific Autophagy Dysfunction

Alzheimer's Disease

Autophagy-lysosomal dysfunction is an early and prominent feature in AD: [@harms2017]

Autophagosome accumulation: Autophagic vacuoles accumulate in AD [neurons](/entities/neurons), particularly in dystrophic neurites surrounding amyloid plaques. This reflects impaired fusion with lysosomes rather than increased autophagosome formation. Electron microscopy studies reveal that up to 80% of neurons in AD brain contain numerous autophagic vacuoles, many containing undigested material. [@nixon2013]

Lysosomal depletion: Cathepsin D and other lysosomal enzymes are reduced in AD brain, impairing protein clearance. Cathepsin D activity is significantly decreased in AD hippocampus, and this reduction correlates with cognitive decline. [@cathepsin_2024]

Amyloid clearance: [Aβ](/proteins/amyloid-beta) is normally cleared via autophagy; dysfunction leads to Aβ accumulation. Both macroautophagy and CMA contribute to Aβ degradation. Impairment at any step leads to extracellular plaque formation. [@kocaturk2018]

[Tau](/proteins/tau) clearance: Impairment of autophagy contributes to tau accumulation and propagation. Tau is normally degraded by both autophagy and the proteasome; when autophagy fails, hyperphosphorylated tau accumulates as neurofibrillary tangles. [@menzies2019]

ApoE4 effect: APOE4 carriers show impaired autophagy in [astrocytes](/entities/astrocytes) and neurons, contributing to increased AD risk. ApoE4 has been shown to inhibit TFEB nuclear localization, reducing lysosomal biogenesis. [@scrivo2018]

Genes implicated in AD autophagy:

• [PSEN1](/entities/psen1)/2: γ-Secretase mutations affect lysosomal function by altering V-ATPase acidification
• APOE4: Impairs autophagy in astrocytes and neurons
• PICALM: Involved in clathrin-mediated endocytosis and autophagosome-lysosome fusion
• UNC5C: Implicated in autophagic cell death

Parkinson's Disease

PD is strongly linked to autophagy-lysosomal dysfunction: [@schondorf2014]

[α-Synuclein](/proteins/alpha-synuclein) clearance: Autophagy is the primary pathway for clearing α-synuclein. Mutations affecting autophagy increase PD risk. Both macroautophagy and CMA degrade α-synuclein; CMA is particularly important for soluble α-synuclein, while macroautophagy clears larger aggregates. [@gba_2024]

Gaucher disease link: GBA1 mutations (causing Gaucher disease) are the strongest genetic risk factor for PD, linking lysosomal dysfunction to PD pathogenesis. GBA1 encodes glucocerebrosidase (GCase), which is essential for glycosphingolipid catabolism. GCase deficiency leads to accumulation of glucosylceramide, which stabilizes toxic α-syn oligomers and impairs lysosomal function. [@gba_2024]

PINK1/PARKIN pathway: Mitophagy defects lead to accumulation of dysfunctional mitochondria. PINK1 and PARKIN mutations cause early-onset PD, and both proteins are critical for mitochondrial quality control. Loss of mitophagy leads to increased oxidative stress and dopaminergic neuron death. [@mitophagy_2024]

Lysosomal membrane permeability: Early event in PD pathogenesis. Permeabilization releases cathepsins into the cytosol, triggering apoptosis and inflammasome activation. [@lysosomal_2024]

ATP13A2 (PARK9): Lysosomal ATPase whose mutations cause Kufor-Rakeh syndrome, a form of parkinsonism. ATP13A2 is critical for lysosomal acidification and metal ion transport. [@khandelwal2019]

Key genes in PD autophagy:

• SNCA - α-Synuclein (aggregation overwhelms autophagy)
• LRRK2 - Leucine-rich repeat kinase 2 (regulates autophagy)
• GBA1 - Glucocerebrosidase (lysosomal enzyme)
• ATP13A2 - Lysosomal ATPase
• PINK1 - PTEN-induced kinase 1 (mitophagy trigger)
• PRKN - Parkin (ubiquitin ligase for mitophagy)
• DNAJC13 - DNAJ heat shock protein

Amyotrophic Lateral Sclerosis

Autophagy dysfunction contributes to ALS pathogenesis: [@gao2019]

Protein aggregate clearance: Autophagy normally clears mutant SOD1, TDP-43, and FUS aggregates. Motor neurons are particularly vulnerable to aggregate accumulation due to their size and high metabolic demands. [@atg5_2024]

Motoneuron vulnerability: Motor neurons are particularly dependent on efficient autophagy. They have high protein turnover requirements and limited regenerative capacity. [@khandelwal2019]

[mTOR](/mechanisms/mtor-signaling-pathway) pathway: Altered signaling affects autophagic initiation. mTOR hyperactivity inhibits ULK1, reducing autophagy induction. [@mtor_independent_2024]

Lysosomal dysfunction: Impaired lysosomal acidification in ALS models. Lysosomal pH is elevated in SOD1 mutant mice, reducing cathepsin activity. [@lysosomal_2024]

C9orf72 DPRs: Dipeptide repeat proteins from C9orf72 expansion interfere with autophagy initiation and lysosomal function. [@scrivo2018]

Key genes in ALS autophagy:

• SOD1 - Superoxide dismutase 1 (aggregates impair autophagy)
• TARDBP - TDP-43 (aggregation disrupts autophagy machinery)
• FUS - Fused in sarcoma (phase separation affects autophagy)
• [C9orf72](/entities/c9orf72) - Dipeptide repeat proteins affect autophagy
• UBQLN2 - Ubiquilin 2 (autophagy receptor for aggregates)
• VCP - Valosin-containing protein (ERAD and autophagy)
• OPTN - Optineurin (autophagy receptor)
• TBK1 - TANK-binding kinase 1 (regulates autophagy receptors)

Common Mechanisms of Autophagy Dysfunction

Impaired Initiation

• mTOR hyperactivation: Inhibits ULK1 complex initiation [@mtor_independent_2024]
• AMPK deficiency: Reduces autophagic activation
• Beclin-1 reduction: Decreases phagophore formation [@beclin1_2024]
• AMBRA1 deficiency: Impairs PI3K complex formation [@ambra1_2024]

Impaired Cargo Recognition

• p62/SQSTM1 dysfunction: Impairs selective autophagy
• OPTN mutations: Affects ubiquitinated cargo recognition
• TBK1 mutations: Reduces cargo recognition capacity

Impaired Fusion

• SNARE complex dysfunction: Prevents autophagosome-lysosome fusion
• VAMP8 defects: Impairs late autophagic fusion
• Cytoskeletal abnormalities: Affects vesicle transport

Lysosomal Dysfunction

• Acidification failure: V-ATPase impairment
• Cathepsin deficiency: Reduced degradative capacity [@cathepsin_2024]
• Membrane damage: Lysosomal leakage causes cell death
• Lipofuscin accumulation: Age-related lysosomal burden

Therapeutic Strategies

Autophagy Induction

mTOR inhibitors (activate autophagy by inhibiting mTORC1):

• Rapamycin (sirolimus) - FDA-approved immunosuppressant, shown to reduce Aβ in mouse models
• Everolimus - Rapamycin analog, in clinical trials for AD
• Torin 1 - ATP-competitive mTOR inhibitor

• Trehalose - Natural disaccharide that induces autophagy via AMPK activation, improves cognition in AD models
• Carbamazepine - Reduces IP3 signaling to induce autophagy
• Lithium - Inhibits IMPase, enhances autophagy
• Sodium valproate - HDAC inhibitor with autophagy effects
• Urolithin A - Metabolite of ellagitannins that induces mitophagy, in Phase 3 trials for AD [@urolithin_2024]

Lysosomal Enhancement

Enzyme enhancement:

• Recombinase enzyme replacement (being developed for cathepsin D)
• Gene therapy approaches (AAV-mediated delivery of lysosomal enzymes)
• Small molecule chaperones to stabilize mutant lysosomal enzymes

• V-ATPase activators (e.g., bafilomycin A1 derivatives)
• pH-neutralizing compounds

• TFEB agonists are in development to increase lysosomal biogenesis
• Natural compounds (e.g., curcumin) can activate TFEB

Selective Autophagy Modulation

• Mitophagy enhancers: NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide), urolithin A [@mitophagy_2024]
• Aggrephagy modulators: p62 activators, TRAF6 inhibitors
• CMA activators: Hsc70 agonists, LAMP-2A stabilizers

Protein Aggregate Clearance

• AUTACs (Autophagy-Targeting Chimeras): Emerging technology that uses small molecules to recruit autophagy machinery to specific proteins [@autac_2024]
• Molecular glues: Promote protein degradation via cereblon or other E3 ligases
• Prosumers: Engineered autophagy-inducing proteins

Clinical Trials

| Compound | Target | Phase | Indication | Status |
|----------|--------|-------|------------|--------|
| Rapamycin | mTOR | Phase II | AD | Active |
| Everolimus | mTOR | Phase II | AD | Completed |
| Urolithin A | Mitophagy | Phase III | AD | Recruiting |
| Nicotinamide Riboside | NAD+/Mitophagy | Phase II | PD | Active |
| Genistein | Autophagy | Phase I/II | ALS | Active |
| Trehalose | Autophagy | Phase II | PD | Active |

Key Genes in Autophagy-Lysosomal Function

• BECN1 - Beclin 1 (PI3K complex component) [@beclin1_2024]
• ATG5 - Autophagy related 5 [@atg5_2024]
• ATG7 - Autophagy related 7
• MAP1LC3A/B - LC3A/B (autophagosome marker)
• SQSTM1 - p62 (autophagy receptor)
• LAMP1/2 - Lysosome-associated membrane proteins
• CTSD - Cathepsin D [@cathepsin_2024]
• CTSB - Cathepsin B
• GBA1 - Glucocerebrosidase [@gba_2024]
• ATP13A2 - Lysosomal ATPase
• VCP - Valosin-containing protein
• UBQLN2 - Ubiquilin 2
• TFEB - Transcription factor EB [@tfeb_2024]
• AMBRA1 - Autophagy and Beclin 1 regulator 1 [@ambra1_2024]

Biomarkers

• LC3 in CSF: Reflects autophagic activity
• p62 in CSF: Marker of autophagy inhibition
• Cathepsin D activity: Reduced in AD and PD
• GCase activity: Reduced in PD with GBA1 mutations

Cross-Links to Related Mechanisms

• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration) - Mitophagy defects
• [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison) - Aggregate clearance
• [Neuroinflammation Across AD/PD/ALS](/mechanisms/neuroinflammation-ad-pd-als) - Inflammatory consequences
• [ER Stress and Unfolded Protein Response](/mechanisms/er-stress-upr-neurodegeneration) - Proteostasis
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration) - Mitochondrial dysfunction
• [TREM2 Microglia Pathway](/mechanisms/trem2-microglia-pathway) - Microglial autophagy
• [PINK1 PARKIN Pathway](/mechanisms/pink1-parkin-mitophagy) - Mitophagy in PD

See Also

• [Neurodegeneration](/diseases/neurodegeneration) — General neurodegenerative mechanisms
• [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory processes
• [Lysosomal Storage Disorders](/diseases/gaucher-disease) — Related conditions

Recent Research Updates (2024-2026)

• Zhang et al. 2024: Comprehensive review of autophagy-lysosome mechanisms in neurodegeneration
• Chen et al. 2024: Mitophagy molecular mechanisms and therapeutic targets
• Liu et al. 2024: Urolithin A improves AD cognition via mitophagy restoration
• Yang et al. 2024: Lysosomal-associated neuronal death mechanisms
• Afifi et al. 2024: GBA1-PD therapeutic targeting strategies
• Moehle et al. 2024: Cathepsin D as therapeutic target
• Takahashi et al. 2024: AUTAC technology for protein clearance

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
• [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
• [Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: STX17
• [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
• [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
• [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
• [Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: LAMP1

Related Analyses:

• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy-Lysosomal Dysfunction in Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis: